Stately Bio is a biotechnology company building machine learning for regenerative medicine through a live-cell imaging platform. Its ML-driven imaging platform identifies and monitors cells in real time using label-free, live-cell compatible imaging without fluorescent tags or genetic modification. The technology quantifies diverse cell types, tracks differentiation progress, optimizes protocols, and can forecast manufacturing outcomes to accelerate process development and improve quality control for biopharma. On the discovery side, the company has applied the platform to improve differentiation of stem cells into mature cells, beginning with an industry-leading liver cell program. Its liver cells show 3x–10x improvement across a panel of metabolic assays of key liver functions versus the state of the art. Stately Bio plans to expand to additional cell types and is actively seeking partners for toxicity testing, disease modeling, and therapeutics. The company raised $12m in seed funding to scale its platform technology and mature its internal pipeline.

Total raised

$12M

Funding rounds

1

Latest round

Seed

Latest activity

May 2025